Titre : Mitomycine

Mitomycine : Questions médicales fréquentes

Termes MeSH sélectionnés :

Eye-Tracking Technology
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Mitomycine : Questions médicales les plus fréquentes", "headline": "Mitomycine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Mitomycine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-23", "dateModified": "2025-02-17", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Mitomycine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Mitomycines", "url": "https://questionsmedicales.fr/mesh/D008937", "about": { "@type": "MedicalCondition", "name": "Mitomycines", "code": { "@type": "MedicalCode", "code": "D008937", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.473.412.249" } } }, "about": { "@type": "MedicalCondition", "name": "Mitomycine", "alternateName": "Mitomycin", "code": { "@type": "MedicalCode", "code": "D016685", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Elise Champeil", "url": "https://questionsmedicales.fr/author/Elise%20Champeil", "affiliation": { "@type": "Organization", "name": "John Jay College of Criminal Justice, New York, 524 West 59(th) Street, New York, NY 10019, USA; The Graduate Center of the City University of New York, New York, NY 10016, USA. Electronic address: echampeil@jjay.cuny.edu." } }, { "@type": "Person", "name": "Owen Zacarias", "url": "https://questionsmedicales.fr/author/Owen%20Zacarias", "affiliation": { "@type": "Organization", "name": "Department of Sciences, John Jay College of Criminal Justice, New York, NY 10019, United States." } }, { "@type": "Person", "name": "Maggie Zheng", "url": "https://questionsmedicales.fr/author/Maggie%20Zheng", "affiliation": { "@type": "Organization", "name": "John Jay College of Criminal Justice, New York, 524 West 59(th) Street, New York, NY 10019, USA. Electronic address: maggie.zheng@jjay.cuny.edu." } }, { "@type": "Person", "name": "Timothy Snyder", "url": "https://questionsmedicales.fr/author/Timothy%20Snyder", "affiliation": { "@type": "Organization", "name": "John Jay College of Criminal Justice, New York, 524 West 59(th) Street, New York, NY 10019, USA. Electronic address: timothy.snyder@jjay.cuny.edu." } }, { "@type": "Person", "name": "Gloria Proni", "url": "https://questionsmedicales.fr/author/Gloria%20Proni", "affiliation": { "@type": "Organization", "name": "John Jay College of Criminal Justice, New York, 524 West 59(th) Street, New York, NY 10019, USA. Electronic address: gproni@jjay.cuny.edu." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "An EEG & eye-tracking dataset of ALS patients & healthy people during eye-tracking-based spelling system usage.", "datePublished": "2024-06-22", "url": "https://questionsmedicales.fr/article/38909069", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41597-024-03501-y" } }, { "@type": "ScholarlyArticle", "name": "The promise of eye-tracking in the detection of concealed memories.", "datePublished": "2022-09-21", "url": "https://questionsmedicales.fr/article/36153230", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.tics.2022.08.019" } }, { "@type": "ScholarlyArticle", "name": "A dual mobile eye tracking study on natural eye contact during live interactions.", "datePublished": "2023-07-14", "url": "https://questionsmedicales.fr/article/37452135", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-023-38346-9" } }, { "@type": "ScholarlyArticle", "name": "Children's processing of written irony: An eye-tracking study.", "datePublished": "2023-06-13", "url": "https://questionsmedicales.fr/article/37321036", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.cognition.2023.105508" } }, { "@type": "ScholarlyArticle", "name": "Subclinical involvement of eye movements detected by video-based eye tracking in myasthenia gravis.", "datePublished": "2023-03-27", "url": "https://questionsmedicales.fr/article/36971995", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10072-023-06736-6" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérobicycliques", "item": "https://questionsmedicales.fr/mesh/D006574" }, { "@type": "ListItem", "position": 5, "name": "Indoles", "item": "https://questionsmedicales.fr/mesh/D007211" }, { "@type": "ListItem", "position": 6, "name": "Indolequinones", "item": "https://questionsmedicales.fr/mesh/D045563" }, { "@type": "ListItem", "position": 7, "name": "Mitomycines", "item": "https://questionsmedicales.fr/mesh/D008937" }, { "@type": "ListItem", "position": 8, "name": "Mitomycine", "item": "https://questionsmedicales.fr/mesh/D016685" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Mitomycine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Mitomycine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-06", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Mitomycine", "description": "Comment la mitomycine est-elle administrée ?\nQuels tests sont nécessaires avant traitement ?\nLa mitomycine est-elle utilisée pour tous les cancers ?\nQuels marqueurs tumoraux sont surveillés ?\nY a-t-il des contre-indications au traitement ?", "url": "https://questionsmedicales.fr/mesh/D016685?mesh_terms=Eye-Tracking+Technology&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Mitomycine", "description": "Quels sont les effets secondaires courants ?\nLa mitomycine cause-t-elle des douleurs ?\nQuels symptômes indiquent une réaction allergique ?\nPeut-elle affecter le système immunitaire ?\nQuels signes de toxicité doivent alerter ?", "url": "https://questionsmedicales.fr/mesh/D016685?mesh_terms=Eye-Tracking+Technology&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Mitomycine", "description": "Comment minimiser les effets secondaires ?\nDes vaccinations sont-elles nécessaires ?\nComment éviter les infections pendant le traitement ?\nY a-t-il des recommandations alimentaires ?\nComment gérer le stress pendant le traitement ?", "url": "https://questionsmedicales.fr/mesh/D016685?mesh_terms=Eye-Tracking+Technology&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Mitomycine", "description": "La mitomycine est-elle utilisée seule ?\nQuelle est la durée du traitement ?\nComment surveiller l'efficacité du traitement ?\nQuels soins de soutien sont recommandés ?\nY a-t-il des interactions médicamenteuses ?", "url": "https://questionsmedicales.fr/mesh/D016685?mesh_terms=Eye-Tracking+Technology&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Mitomycine", "description": "Quelles sont les complications possibles ?\nLa mitomycine peut-elle causer des cancers secondaires ?\nComment gérer une toxicité sévère ?\nQuels tests pour surveiller les complications ?\nY a-t-il des effets à long terme ?", "url": "https://questionsmedicales.fr/mesh/D016685?mesh_terms=Eye-Tracking+Technology&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Mitomycine", "description": "Qui est à risque d'effets secondaires ?\nLes antécédents de cancer augmentent-ils le risque ?\nLe tabagisme influence-t-il le traitement ?\nY a-t-il des facteurs génétiques à considérer ?\nL'âge influence-t-il la tolérance au traitement ?", "url": "https://questionsmedicales.fr/mesh/D016685?mesh_terms=Eye-Tracking+Technology&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment la mitomycine est-elle administrée ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "La mitomycine est généralement administrée par injection intraveineuse ou intravésicale." } }, { "@type": "Question", "name": "Quels tests sont nécessaires avant traitement ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des examens d'imagerie sont souvent requis pour évaluer la santé du patient." } }, { "@type": "Question", "name": "La mitomycine est-elle utilisée pour tous les cancers ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Non, elle est principalement utilisée pour des cancers spécifiques comme le cancer de la vessie." } }, { "@type": "Question", "name": "Quels marqueurs tumoraux sont surveillés ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les marqueurs comme le CA 19-9 peuvent être surveillés selon le type de cancer traité." } }, { "@type": "Question", "name": "Y a-t-il des contre-indications au traitement ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents d'allergies ou de maladies rénales peuvent être des contre-indications." } }, { "@type": "Question", "name": "Quels sont les effets secondaires courants ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent nausées, vomissements, et fatigue." } }, { "@type": "Question", "name": "La mitomycine cause-t-elle des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut provoquer des douleurs abdominales ou des douleurs au site d'injection." } }, { "@type": "Question", "name": "Quels symptômes indiquent une réaction allergique ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des démangeaisons, éruptions cutanées ou difficultés respiratoires peuvent indiquer une allergie." } }, { "@type": "Question", "name": "Peut-elle affecter le système immunitaire ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la mitomycine peut réduire les globules blancs, augmentant le risque d'infections." } }, { "@type": "Question", "name": "Quels signes de toxicité doivent alerter ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des saignements inhabituels ou des ecchymoses peuvent indiquer une toxicité." } }, { "@type": "Question", "name": "Comment minimiser les effets secondaires ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une bonne hydratation et des médicaments antiémétiques peuvent aider à réduire les effets secondaires." } }, { "@type": "Question", "name": "Des vaccinations sont-elles nécessaires ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des vaccinations peuvent être recommandées pour prévenir les infections pendant le traitement." } }, { "@type": "Question", "name": "Comment éviter les infections pendant le traitement ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les foules et pratiquer une bonne hygiène peut aider à prévenir les infections." } }, { "@type": "Question", "name": "Y a-t-il des recommandations alimentaires ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et riche en nutriments est recommandée pour soutenir le traitement." } }, { "@type": "Question", "name": "Comment gérer le stress pendant le traitement ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Des techniques de relaxation et le soutien psychologique peuvent aider à gérer le stress." } }, { "@type": "Question", "name": "La mitomycine est-elle utilisée seule ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut être utilisée seule ou en combinaison avec d'autres agents chimiothérapeutiques." } }, { "@type": "Question", "name": "Quelle est la durée du traitement ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La durée varie selon le type de cancer, mais elle est souvent administrée sur plusieurs cycles." } }, { "@type": "Question", "name": "Comment surveiller l'efficacité du traitement ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des examens d'imagerie et des tests sanguins réguliers sont utilisés pour évaluer l'efficacité." } }, { "@type": "Question", "name": "Quels soins de soutien sont recommandés ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des soins de soutien comme la gestion de la douleur et des conseils nutritionnels sont recommandés." } }, { "@type": "Question", "name": "Y a-t-il des interactions médicamenteuses ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la mitomycine peut interagir avec d'autres médicaments, nécessitant une surveillance." } }, { "@type": "Question", "name": "Quelles sont les complications possibles ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent inclure des infections, des saignements et des problèmes rénaux." } }, { "@type": "Question", "name": "La mitomycine peut-elle causer des cancers secondaires ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'utilisation de mitomycine peut augmenter le risque de cancers secondaires à long terme." } }, { "@type": "Question", "name": "Comment gérer une toxicité sévère ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Une hospitalisation et un traitement symptomatique peuvent être nécessaires en cas de toxicité sévère." } }, { "@type": "Question", "name": "Quels tests pour surveiller les complications ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins réguliers et des examens d'imagerie sont nécessaires pour surveiller les complications." } }, { "@type": "Question", "name": "Y a-t-il des effets à long terme ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des effets à long terme peuvent inclure des problèmes pulmonaires ou rénaux, nécessitant un suivi." } }, { "@type": "Question", "name": "Qui est à risque d'effets secondaires ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes âgées et celles avec des antécédents médicaux complexes sont plus à risque." } }, { "@type": "Question", "name": "Les antécédents de cancer augmentent-ils le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de cancer peuvent augmenter le risque d'effets secondaires lors du traitement." } }, { "@type": "Question", "name": "Le tabagisme influence-t-il le traitement ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut affecter l'efficacité du traitement et augmenter les risques d'effets secondaires." } }, { "@type": "Question", "name": "Y a-t-il des facteurs génétiques à considérer ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Certaines variations génétiques peuvent influencer la réponse au traitement par mitomycine." } }, { "@type": "Question", "name": "L'âge influence-t-il la tolérance au traitement ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients plus âgés peuvent avoir une tolérance réduite aux effets de la mitomycine." } } ] } ] }

Sources (10000 au total)

Subclinical involvement of eye movements detected by video-based eye tracking in myasthenia gravis.

Ocular abnormalities in myasthenia gravis (MG) are characterized by severely limited movements and rapid saccades. Data about eye motility of MG patients whose ocular movements are apparently normal a... In this longitudinal study, we screened all patients diagnosed with MG referring to the Neurologic Clinic of the University of Catania between October 1, 2019, and June 30, 2021. Ten age- and sex-matc... A total of 14 MG patients with no clinical signs of ocular motor dysfunction (64.3% men, with a mean age of 50.4 ± 14.4 years) were enrolled. At baseline, saccades in MG patients showed slower velocit... Eye motility is impaired even in MG patients with no clinical evidence of ocular movement disturbance. Video-based eye tracking may detect subclinical involvement of eye movements in patients with MG....

Eye tracking validation: Improving radiologist reporting and interpretation.

This study aims to validate a new radiology reporting style using eye tracking to maximize radiologist interpretation time, increase accuracy, and minimize dictation time, ultimately providing a clini... The positive findings only dictation style using a podcast stand-alone microphone (n = 76) was compared with the standard check-list dictation style using a handheld microphone (n = 81). Experienced b... Eye tracking revealed that the new positive findings dictation style led to a noteworthy shift in radiologists' visual attention, with reduced heat map overlaying the reporting software compared to th... Positive findings only dictation style significantly decreased dictation time and enhanced accuracy without compromising total interpretation time....

Reporting Eye-tracking Studies In DEntistry (RESIDE) checklist.

To (i) provide a scoping review of eye-tracking studies in dentistry, and (ii) propose a "Reporting Eye-tracking Studies in DEntistry" (RESIDE) checklist to facilitate standard reporting of eye-tracki... A comprehensive search of six distinct electronic databases was undertaken.... Pubmed, OVID, Wed of Knowledge, Scopus, Cochrane and Google Scholar were used to identify studies that employed eye-tracking technology and dentistry as a subfield STUDY SELECTION: 42 studies met the ... Evaluation of the published eye-tracking studies in this scoping review provides empirical data, highlighting the inconsistencies and limitations. Importantly, it illustrates the applicability of the ... A minimum threshold should be applied before accepting eye-tracking studies for publication in the future. RESIDE checklist promotes transparent and reproducible scientific communication about eye-tra...

Eye Tracking Use in Surgical Research: A Systematic Review.

Eye tracking (ET) is a popular tool to study what factors affect the visual behaviour of surgical team members. To our knowledge, there have been no reviews to date that evaluate the broad use of ET i... In line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a systematic literature review was conducted. An electronic search was performed in MEDLINE, Cochrane Ce... A total of 7614 studies were identified, and 111 were included for data extraction. Eleven applications were identified; the four most common were skill assessment (41%), visual attention assessment (... This review provided a comprehensive summary of the various applications of ET in surgery and how ET could be used to inform surgical practice, including how to use ET to improve surgical education. T...

Eye-Tracking Biomarkers and Autism Diagnosis in Primary Care.

Finding effective and scalable solutions to address diagnostic delays and disparities in autism is a public health imperative. Approaches that integrate eye-tracking biomarkers into tiered community-b... To determine whether a battery of eye-tracking biomarkers can reliably differentiate young children with and without autism in a community-referred sample collected during clinical evaluation in the p... Early Autism Evaluation (EAE) Hub system PCPs referred a consecutive sample of children to this prospective diagnostic study for blinded eye-tracking index test and follow-up expert evaluation from Ju... The primary outcomes were sensitivity and specificity of a composite eye-tracking (ie, index) test, which was a consolidated measure based on significant eye-tracking indices, compared with reference ... Among 146 children (mean [SD] age, 2.6 [0.6] years; 104 [71%] male; 21 [14%] Hispanic or Latine and 96 [66%] non-Latine White; 102 [70%] with a reference standard autism diagnosis), 113 (77%) had conc... In this prospective diagnostic study, a composite eye-tracking biomarker was associated with a best-estimate clinical diagnosis of autism, and an integrated diagnostic model including PCP diagnosis an...